Rhythm Pharmaceuticals Stock Forecast, Price & News

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rhythm Pharmaceuticals in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Rhythm Pharmaceuticals stock.
View analyst ratings for Rhythm Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Rhythm Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Rhythm Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Rhythm Pharmaceuticals saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 4,160,000 shares, an increase of 54.1% from the March 15th total of 2,700,000 shares. Based on an average trading volume of 485,800 shares, the days-to-cover ratio is presently 8.6 days.
View Rhythm Pharmaceuticals' Short Interest.

Rhythm Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, May 3rd 2021.
View our earnings forecast for Rhythm Pharmaceuticals.

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) posted its earnings results on Sunday, February, 28th. The company reported ($0.79) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.80) by $0.01.
View Rhythm Pharmaceuticals' earnings history.

Rhythm Pharmaceuticals' stock was trading at $15.00 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, RYTM shares have increased by 31.4% and is now trading at $19.71.
View which stocks have been most impacted by COVID-19.

6 Wall Street analysts have issued twelve-month price targets for Rhythm Pharmaceuticals' stock. Their forecasts range from $33.00 to $67.00. On average, they anticipate Rhythm Pharmaceuticals' share price to reach $50.67 in the next year. This suggests a possible upside of 157.1% from the stock's current price.
View analysts' price targets for Rhythm Pharmaceuticals or view top-rated stocks among Wall Street analysts.

1 employees have rated Rhythm Pharmaceuticals CEO on Glassdoor.com. has an approval rating of 100% among Rhythm Pharmaceuticals' employees. This puts in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Rhythm Pharmaceuticals include Agios Pharmaceuticals (AGIO), Atea Pharmaceuticals (AVIR), Apellis Pharmaceuticals (APLS), Turning Point Therapeutics (TPTX), Nektar Therapeutics (NKTR), Legend Biotech (LEGN), PTC Therapeutics (PTCT), Insmed (INSM), ACADIA Pharmaceuticals (ACAD), InnovAge (INNV), Reata Pharmaceuticals (RETA), ChemoCentryx (CCXI), Alkermes (ALKS), Arvinas (ARVN) and Karuna Therapeutics (KRTX).
View all of RYTM's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Rhythm Pharmaceuticals investors own include VBI Vaccines (VBIV), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Viking Therapeutics (VKTX), Amarin (AMRN), (KDMN), Pfizer (PFE), Sangamo Therapeutics (SGMO) and Sarepta Therapeutics (SRPT).

(RYTM) raised $100 million in an initial public offering on Thursday, October 5th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen served as the underwriters for the IPO and Needham was co-manager.

Rhythm Pharmaceuticals trades on the NASDAQ under the ticker symbol "RYTM."

Rhythm Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Pacer Advisors Inc. (0.01%). Company insiders that own Rhythm Pharmaceuticals stock include David P Meeker, Der Ploeg Leonardus HT Van, Nithya Desikan, Ra Capital Management, LP and Todd Foley.
View institutional ownership trends for Rhythm Pharmaceuticals.

RYTM stock was purchased by a variety of institutional investors in the last quarter, including Pacer Advisors Inc..
View insider buying and selling activity for Rhythm Pharmaceuticals or or view top insider-buying stocks.

Shares of RYTM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RYTM stock can currently be purchased for approximately $19.71.

Rhythm Pharmaceuticals has a market capitalization of $989.07 million. The company earns $-140,730,000.00 in net income (profit) each year or ($3.86) on an earnings per share basis.

Rhythm Pharmaceuticals employs 90 workers across the globe.

The official website for Rhythm Pharmaceuticals is www.rhythmtx.com.

Rhythm Pharmaceuticals is headquartered at 222 BERKELEY STREET 12TH FLOOR, BOSTON MA, 02116.

Rhythm Pharmaceuticals' mailing address is 222 BERKELEY STREET 12TH FLOOR, BOSTON MA, 02116. The company can be reached via phone at 857-264-4280 or via email at [email protected]